Dr. Andrew Poklepovic, MD
Claim this profileVirginia Commonwealth University/Massey Cancer Center
Expert in Cancer
Expert in Melanoma
36 reported clinical trials
85 drugs studied
Area of expertise
1Cancer
Global LeaderStage IV
Stage III
PD-L1 positive
2Melanoma
Global LeaderStage IV
Stage III
BRAF positive
Affiliated Hospitals
Clinical Trials Andrew Poklepovic, MD is currently running
Nivolumab + Ipilimumab + Sargramostim
for Advanced Melanoma
This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma.
Recruiting1 award Phase 2 & 323 criteria
Ipatasertib + Chemotherapy
for Cancer
This phase II ComboMATCH treatment trial tests the usual treatment of chemotherapy (paclitaxel) plus ipatasertib in patients with solid tumor cancers that that cannot be removed by surgery (unresectable), has spread to nearby tissue or lymph nodes (locally advanced) or from where it first started (primary site) to other places in the body (metastatic), and has PTEN and AKT genetic changes. Chemotherapy drugs, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Targeted therapy, such as Ipatasertib, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The addition of ipatasertib to paclitaxel in solid tumors with PTEN and AKT genetic changes could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression). Researchers hope to learn if paclitaxel plus ipatasertib will shrink this type of cancer or stop its growth.
Recruiting1 award Phase 2
More about Andrew Poklepovic, MD
Clinical Trial Related5 years of experience running clinical trials · Led 36 trials as a Principal Investigator · 14 Active Clinical TrialsTreatments Andrew Poklepovic, MD has experience with
- Nivolumab
- Pembrolizumab
- Biospecimen Collection
- Ipilimumab
- Paclitaxel
- Ipatasertib
Breakdown of trials Andrew Poklepovic, MD has run
Cancer
Melanoma
Skin Cancer
Pancreatic Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Andrew Poklepovic, MD specialize in?
Andrew Poklepovic, MD focuses on Cancer and Melanoma. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Andrew Poklepovic, MD currently recruiting for clinical trials?
Yes, Andrew Poklepovic, MD is currently recruiting for 14 clinical trials in Richmond Virginia. If you're interested in participating, you should apply.
Are there any treatments that Andrew Poklepovic, MD has studied deeply?
Yes, Andrew Poklepovic, MD has studied treatments such as Nivolumab, Pembrolizumab, Biospecimen Collection.
What is the best way to schedule an appointment with Andrew Poklepovic, MD?
Apply for one of the trials that Andrew Poklepovic, MD is conducting.
What is the office address of Andrew Poklepovic, MD?
The office of Andrew Poklepovic, MD is located at: Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia 23298 United States. This is the address for their practice at the Virginia Commonwealth University/Massey Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.